ArticleBritish journal of clinical pharmacology2022
Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing.
Article in British journal of clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Assessment of chemotherapy-associated sarcopenia using SARC-F and handgrip strength: a cross-sectional analysis.Annals of medicine and surgery (2012) · 2026Article
- Loganin, an Iridoid Glycoside, Alleviates Paclitaxel-Induced Skeletal Muscle Toxicity by Enhancing Mitochondrial Function, Boosting Antioxidant Defenses, and Reducing Cellular Senescence.The Kaohsiung journal of medical sciences · 2026Article
- Obesity and Tolerance to Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Cohort Study.Cancers · 2026Article
- Artificial intelligence standardizes CT-based body composition analysis in breast cacer to address methodological heterogeneity.Frontiers in oncology · 2026Review
- The relationship between sarcopenia and breast cancer: mechanistic pathways and clinical relevance.Frontiers in cell and developmental biology · 2026Review
- Exploratory analysis of the association between body composition albumin-bound paclitaxel induced peripheral neuropathy.Frontiers in pharmacology · 2026Article
- Impact of sarcopenia on paclitaxel-induced peripheral neuropathy in early-stage breast cancer: a prospective observational study (the neuro-sarc study).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Observational
- Pharmacokinetic-Pharmacodynamic Model of Paclitaxel-Induced Peripheral Neuropathy.Clinical and translational science · 2025Article
- Review
- The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study.Breast cancer research and treatment · 2025Observational
- Article
- Using maximum plasma concentration (CCancer chemotherapy and pharmacology · 2024Review
- Evolution of predictive risk factor analysis for chemotherapy-related toxicity.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Review
- Genetic variations that influence paclitaxel pharmacokinetics and intracellular effects that may contribute to chemotherapy-induced neuropathy: A narrative review.Frontiers in pain research (Lausanne, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
aimsPatients with low muscle mass have increased risk of paclitaxel-induced peripheral neuropathy, which is dependent on systemic paclitaxel exposure. Dose optimization may be feasible through the secondary use of radiologic data for body composition. The objective of this study was to interrogate morphomic parameters as predictors of paclitaxel pharmacokinetics to identify alternative dosing strategies that may improve treatment outcomes.
methodsThis was a secondary analysis of female patients with breast cancer scheduled to receive 80 mg/m
resultsThirty-nine patients were included in the analysis. The optimal model was a two-compartment pharmacokinetic model with T11 skeletal muscle area as a covariate of paclitaxel volume of distribution (Vd). Simulations suggest that extending infusion of the standard paclitaxel dose from 1 hour to 2 and 3 hours in patients who have skeletal muscle area 4907-7080 mm
conclusionExtending paclitaxel infusion duration in ~25% of patients who have low skeletal muscle area is predicted to reduce peripheral neuropathy while maintaining systemic exposure, suggesting that personalizing paclitaxel dosing based on body composition may improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.